Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension.

J Cardiovasc Pharmacol

*Clinica Medica, Università Milano-Bicocca, Milan, Italy; †Department of Cardiology, Gulhane Military Medical Academy, Ankara, Turkey; ‡Department of Cardiology, Beytepe Military Hospital, Beytepe, Ankara, Turkey; §Department of Medical Biochemistry, Gulhane Military Medical Academy, Ankara, Tureky; ¶GATA Haydarpasa Eğitim Hastanesi Kardiyoloji Servisi, Istanbul, Turkey; ‖Department of Epidemiology, Gulhane Military Medical Academy, Ankara, Turkey; and **Istituto di Ricerche a Carattere Scientifico IRCCS Multimedica, Milan, Italy.

Published: October 2013

High level of circulating red cell distribution width (RDW) and neutrophil/lymphocyte (N/L) ratio may reflect ongoing vascular inflammation and play an important role in pathophysiology of hypertension. We evaluate the effects of nebivolol and metoprolol on the RDW and N/L in new essential hypertensive patients. After baseline assessment, 72 patients were randomly allocated to 5 mg/d of nebivolol (n = 37, 20 men) or 100 mg/d of metoprolol (n = 35, 18 men) and treated for 6 months. Blood pressure (BP), heart rate (HR), RDW, and N/L were measured before and after treatment. BP significantly decreased with both drugs (P < 0.001). Analog reduction was observed for resting HRs (P < 0.001), but metoprolol caused greater HR fall as compared with nebivolol (P < 0.001). After 6 months of treatment, nebivolol significantly lowered not only RDW but also the total white blood cell and N/L (P < 0.001, P = 0.023, P = 0.017, respectively). No changes were observed in metoprolol group. Percent decrease in RDW was found to be significantly higher in nebivolol than in the metoprolol group (P = 0.001) and remained also after correction for confounders (P = 0.012). Nebivolol improved RDW and N/L to a greater extent than metoprolol in patients with hypertension. These favorable effects may participate, together with the BP reduction, at the favorable properties of the drug in hypertension.

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0b013e31829f716aDOI Listing

Publication Analysis

Top Keywords

nebivolol metoprolol
12
rdw n/l
12
effects nebivolol
8
red cell
8
cell distribution
8
distribution width
8
metoprolol group
8
nebivolol
7
metoprolol
7
rdw
6

Similar Publications

Background: Historically, β-blockers have been associated with erectile dysfunction (ED). Nebivolol, a third-generation β-blocker, may have had no negative effect on erectile function because of its vasodilating properties. However, the evidence level was considered either as low or very low.

View Article and Find Full Text PDF

Introduction: β-Blockers are essential for cardiovascular disease management but can induce respiratory issues, particularly with non-selective β-blockers. Their safety in asthmatic patients is debated.

Objective: This study investigates the link between different classes of β-blockers and the risk of asthma and asthma-like adverse events (AEs) using data from the Food and Drug Administration's Adverse Event Reporting System (FAERS).

View Article and Find Full Text PDF

Position of Beta-blockers in the Treatment of Hypertension Today: An Indian Consensus.

J Assoc Physicians India

October 2024

Senior Consultant Cardiologist and Chairman, Department of Cardiology, Sir Ganga Ram Hospital, New Delhi, India.

Article Synopsis
  • Management of essential hypertension (HTN) is challenging, with less than 10% of cases controlled according to the latest guidelines from the ACC and ISH.
  • Recent updates, including the ESH 2023 guidelines, highlight the evolving role of beta-blockers, particularly in the context of specific Indian health traits related to cardiovascular disease.
  • An expert panel reached a consensus that beta-blockers, especially nebivolol, are effective first-line treatments for HTN, especially in young patients and those with high resting heart rates.
View Article and Find Full Text PDF

Beta-blockers are first-line drugs in the treatment of chronic heart failure (CHF). However, there is no consensus on the specific effects of the beta-blockers of the I-III generation on energy metabolism in CHF. The aim of this study is to conduct a study of beta-blockers of different generations on myocardial energy metabolism in experimental CHF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!